DocGo (NASDAQ:DCGO) Given New $6.50 Price Target at Stifel Nicolaus

DocGo (NASDAQ:DCGO) had its price target lowered by Stifel Nicolaus from $8.00 to $6.50 in a research note issued on Tuesday, Benzinga reports. The firm currently has a “buy” rating on the stock. Stifel Nicolaus’ price objective would suggest a potential upside of 79.56% from the company’s previous close.

Other equities research analysts have also recently issued reports about the company. Canaccord Genuity Group reduced their price objective on DocGo from $10.00 to $9.00 and set a “buy” rating on the stock in a research note on Thursday, April 11th. Cantor Fitzgerald dropped their target price on DocGo from $13.00 to $11.00 and set an “overweight” rating for the company in a research report on Thursday, February 29th. BTIG Research lowered their price target on DocGo from $13.00 to $11.00 and set a “buy” rating for the company in a report on Wednesday, April 10th. Finally, Needham & Company LLC reduced their price objective on shares of DocGo from $14.00 to $10.00 and set a “buy” rating for the company in a research note on Thursday, February 29th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $10.58.

DocGo Stock Up 0.3 %

NASDAQ:DCGO opened at $3.62 on Tuesday. The business’s 50-day simple moving average is $3.71 and its two-hundred day simple moving average is $4.53. The stock has a market cap of $377.10 million, a PE ratio of 51.71, a P/E/G ratio of 0.36 and a beta of 0.91. DocGo has a 52 week low of $2.78 and a 52 week high of $10.82.

DocGo (NASDAQ:DCGO) last issued its earnings results on Wednesday, February 28th. The company reported $0.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.13 by ($0.07). DocGo had a return on equity of 2.01% and a net margin of 1.10%. The firm had revenue of $199.25 million during the quarter, compared to the consensus estimate of $195.48 million. Sell-side analysts anticipate that DocGo will post 0.35 earnings per share for the current fiscal year.

Insider Transactions at DocGo

In other DocGo news, Director Michael J. Burdiek purchased 10,000 shares of DocGo stock in a transaction dated Thursday, March 14th. The shares were acquired at an average cost of $3.61 per share, with a total value of $36,100.00. Following the completion of the transaction, the director now owns 571,595 shares in the company, valued at approximately $2,063,457.95. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders own 13.78% of the company’s stock.

Hedge Funds Weigh In On DocGo

Hedge funds have recently made changes to their positions in the company. AJOVista LLC acquired a new position in shares of DocGo in the 4th quarter valued at $25,000. Victory Capital Management Inc. acquired a new position in shares of DocGo in the 3rd quarter valued at $55,000. Cape Investment Advisory Inc. acquired a new position in shares of DocGo in the 4th quarter valued at $63,000. Verdence Capital Advisors LLC acquired a new position in shares of DocGo in the 1st quarter valued at $64,000. Finally, Envestnet Portfolio Solutions Inc. acquired a new position in shares of DocGo in the 3rd quarter valued at $67,000. 56.44% of the stock is owned by institutional investors and hedge funds.

DocGo Company Profile

DocGo Inc provides mobile health and medical transportation services for various health care providers in the United States and the United Kingdom. The company's transportation services include emergency response services; and non-emergency transport services comprise ambulance and wheelchair transportation services.